PURPOSE: To evaluate bFFF by risk group and treatment modality and the predictive factors of bFFF by risk group in patients with prostate cancer undergoing permanent seed implantation (PI) ± external beam radiation therapy (EBRT) in a nationwide prospective cohort study in Japan (J-POPS) during the first 2 years. METHODS AND MATERIALS: The analyses included 2,316 participants. BFFF was evaluated using the Phoenix definition. The Cox proportional hazards model was used to identify the factors associated with bFFF. RESULTS: Median follow-up period was 60.0 months. The 5-year bFFF rates in all patients, 1,028 low-risk patients, 1,114 intermediate-risk patients, and 133 high-risk patients were 93.6%, 94.9%, 92.7%, and 91.1%, respectively. The 5-year bFFF rates in the PI group and EBRT combination therapy group were 93.7% and 93.3%, respectively. In a multivariate analysis, younger age, higher Gleason score (GS), higher percent positive biopsies (%PB), and lower prostate V100 (p=0.0012, 0.0030, 0.0026, and 0.0368) in all patients; younger age, higher pretreatment prostate-specific antigen (PSA), and lower prostate V100 (p=0.0002, 0.0048, and 0.0012) in low-risk patients; higher GS, higher %PB, and no hormonal treatment (p=0.0005, 0.0120, and 0.0022) in intermediate-risk patients; and higher GS and higher %PB (p=0.0329 and 0.0120) in high-risk patients were significantly associated with bFFF. CONCLUSIONS: PI ± EBRT resulted in excellent short-term biochemical outcomes in all risk groups, especially in high-risk patients. Age, pretreatment PSA, and prostate V100 in low-risk patients; GS, %PB, and hormonal treatment in intermediate-risk patients; and GS and %PB in high-risk patients were independently affected bFFF.
Radium-223 treatment reduces the risk of death in patients with metastatic castration-resistant prostate cancer (CRPC). This study analyzed the prognostic factors in patients treated with radium-223 dichloride.
Background/Aim: Eribulin mesylate has been approved for advanced or metastatic breast cancers subjected to at least two previous chemotherapy regimens. The present multicenter, phase II, single-arm study assessed the efficacy and safety of a first-line regimen of eribulin plus trastuzumab for untreated advanced or metastatic HER2-positive breast cancer. Patients and Methods: Enrolled patients received eribulin (1.4 mg/m2 intravenously; I.V.) on days 1 and 8 of each 21-day cycle, an initial trastuzumab dose (8 mg/kg I.V.) on day 1, and 6 mg/kg of trastuzumab on day 1 of each subsequent cycle. The primary endpoint was the response rate (RR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. Twenty-eight patients (median age: 62.5 years) received a median of 12 (range: 2–53) cycles of eribulin plus trastuzumab. Results: The RR was 53.6% [complete response (CR), 4; partial response (PR), 11] with a median PFS of 344 days. The clinical benefit rate was 64.0%. Grade 3/4 adverse events were observed in 12 (42.9%) patients. For details, neutropenia in 8 (28.6%) patients, peripheral neuropathy in 2 (7.1%) patients, interstitial pneumonia in 1 (3.6%) patient, ALT elevation in 1 (3.6%) patient, osteonecrosis of the jaw in 1 (3.6%) patient, and fatigue in 1 (3.6%) patient. The patient with osteonecrosis received denosumab, too. No symptomatic congestive heart failure was observed. Conclusion: Combination therapy of eribulin plus trastuzumab is acceptable in efficacy and safety, and a capable option for first-line advanced or recurrent HER2-positive breast cancer.
We have studied the binding of collagen fibers with platelet proteins using affinity chromatography on collagen-Sepharose.Only a few proteins from a platelet lysate were trapped by this column.When denatured collagen (gelatin) was used as the affinity ligand, the major protein did not bind and was identified as platelet Factor XI11 by polyacrylamide gel electrophoresis, immunoprecipitation, and enzymic activity.This is a zymogen form of transglutaminase, which corresponds to the "a" subunit of the coagulation factor in plasma.Immunoglobulins specific for platelet Factor XI11 obtained from antiserum raised against plasma Factor XI11 were able to initiate platelet aggregation by themselves, in strong contrast to nonspecific antibodies.This specific immunoglobulin-mediated platelet aggregation required the presence of Ca2+.It was inhibited by aspirin and prostacyclin, but not by specific inhibitors for other agonists.These data suggest the possibility that the zymogen form of Factor XI11 is located on the surface of platelets and may play a key role as the receptor for collagen-induced platelet aggregation.
